skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Inhaled iloprost for the control of pulmonary hypertension

Review

(2963) Views  (1097) Full article downloads

Authors: Sabine Krug, Armin Sablotzki, Stefan Hammerschmidt, Hubert Wirtz, Hans-Juergen Seyfarth

Published Date May 2009 Volume 2009:5 Pages 465 - 473
DOI: http://dx.doi.org/10.2147/VHRM.S3223

Sabine Krug1, Armin Sablotzki2, Stefan Hammerschmidt1, Hubert Wirtz1, Hans-Juergen Seyfarth1

1University of Leipzig, Department of Respiratory Medicine, Germany; 2Klinikum St. Georg Leipzig, Clinics of Anaesthesiology, Critical Care and Pain Therapy, Germany

Abstract: Pulmonary arterial hypertension (PAH) is a life-threatening disease characterized by an elevated pulmonary arterial pressure and vascular resistance with a poor prognosis. Various pulmonary and extrapulmonary causes are now recognized to exist separately from the idiopathic form of pulmonary hypertension. An imbalance in the presence of vasoconstrictors and vasodilators plays an important role in the pathophysiology of the disease, one example being the lack of prostacyclin. Prostacyclin and its analogues are potent vasodilators with antithrombotic, antiproliferative and anti-inflammatory qualities, all of which are important factors in the pathogenesis of precapillary pulmonary hypertension. Iloprost is a stable prostacyclin analogue available for intravenous and aerosolized application. Due to the severe side effects of intravenous administration, the use of inhaled iloprost has become a mainstay in PAH therapy. However, owing to the necessity for 6 to 9 inhalations a day, oral treatment is often preferred as a first-line therapy. Numerous studies proving the efficacy and safety of inhaled iloprost have been performed. It is therefore available for a first-line therapy for PAH. The combination with endothelin-receptor antagonists or sildenafil has shown encouraging effects. Further studies with larger patient populations will have to demonstrate the use of combination therapy for long-term treatment of pulmonary hypertension.

Keywords: pulmonary arterial hypertension, prostacyclin, iloprost, inhaled








Readers of this article also read:

Gamma knife radiosurgery for uveal melanoma ineligible for brachytherapy by the Collaborative Ocular Melanoma Study criteria
Redefining the role of thiazolidinediones in the management of type 2 diabetes
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Berberine: metabolic and cardiovascular effects in preclinical and clinical trials
Feasibility and effectiveness of a disease and care management model in the primary health care system for patients with heart failure and diabetes (Project Leonardo)
Volumetric capnography: In the diagnostic work-up of chronic thromboembolic disease
ABO and rhesus blood group distribution in Kurds
Retinal nerve fiber layer thickness in recovered and persistent amblyopia
Detection of retinal changes in Parkinson's disease with spectral-domain optical coherence tomography
Clinical utility of rosuvastatin and other statins for cardiovascular risk reduction among the elderly
  • Join ISVH

    Be part of the World's leading experts in vascular health by joining the International Society of Vascular Health (ISVH)

  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University